Roche Holding AG

10/14/2021 | Press release | Distributed by Public on 10/14/2021 05:39

FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19

Investor Update

FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19

Dear Investor,

Please find attached a press release from our partner Regeneron:
https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-review

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: [email protected]

 Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: [email protected]
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected]

 Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected]
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected] 		Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: [email protected]
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]